## Incident suicidal ideations in patients with overweight or obesity within 6-month time window (comparison between propensity-score matched groups)

Population	Semaglutide group	Non-GLP1R agonist anti-obesity medications group	)	HR (95% CI)
Overall (n = 52,783/group)	0.11% (60)	0.43% (226)	<del>  ■  </del>	0.27 (0.20–0.36)
Women (n = 39,004/group)	0.11% (43)	0.35% (136)	├ <del>-</del>	0.32 (0.23–0.45)
Men (n = 13,191/group)	0.13% (17)	0.64% (85)	<b>├</b> ■┤	0.20 (0.12–0.34)
age <= 45 years (n = 19,650/group)	0.17% (33)	0.51% (100)		0.34 (0.23–0.50)
age 46-64 years (n = 24,508/group)	0.09% (22)	0.34% (84)	<del>  </del>	0.26 (0.16–0.42)
age >= 65 years (n = 8,106/group)	0.12% (10)	0.31% (25)	<b>├-</b>	0.28 (0.12–0.64)
Black (n = 8,288/group)	0.12% (10)	0.42% (35)	— <del>■</del>	0.20 (0.09–0.45)
White (n = 37,133/group)	0.14% (50)	0.39% (145)	<del>  -  </del>	0.35 (0.25–0.48)
Hispanic ethnicity (n = 3,666/group)	0.27% (10)	0.49% (18)	0.10 0.20 0.40 0.80	0.40 (0.17–0.95)

Hazard Ratio (HR)